Jefferies Reiterates Buy Rating on Vaxcyte (PCVX): "adult PCV alone increasingly supports a materially higher long-term valuation"
Jefferies analyst Roger Song reiterated a Buy rating and $146.00 price target on Vaxcyte (NASDAQ: PCVX)The analyst commented, "At a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)